---
title: "Characteristics of Regulatory Approval of Innovative vs. Non-Innovative Cancer Drugs, Health Policy"
publishDate: "2019-06-04T00:00:00Z"
authors: 
 - knvokinger_author
 - Aaron S. Kesselheim
publication_types: ["2"]
abstract: "Successful first-generation drugs can be converted with small alterations to second-generation drugs, which are cheaper to develop and may pose less financial risk for manufacturers due to already validated action mechanism and a well-defined consumer market."
featured: False
publication: "*Health Policy*"
url_pdf: "https://reader.elsevier.com/reader/sd/pii/S0168851019301538?token=70138DF90ED1358022DEDC3E52135A37332E4642BB53C950DA773E2C4EC6E776F080FEF25607FD359AB8C54BF75E4EC4"
doi: "https://doi.org/10.1016/j.healthpol.2019.06.002"
---
